Secondary Logo

Editorial introductions

Section Editor(s): Slavin, Monica A.; Chemaly, Roy F.; Clark, Tristan W.; Bassetti, Matteo

Current Opinion in Infectious Diseases: December 2018 - Volume 31 - Issue 6 - p vii–viii
doi: 10.1097/QCO.0000000000000506

Current Opinion in Infectious Diseases was launched in 1988. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of infectious diseases is divided into 11 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

Back to Top | Article Outline


Monica A. Slavin

Dr Monica A. Slavin is a Professor in the Department of Medicine at the University of Melbourne, Australia. She is the Director of the Department of Infectious Diseases at the Peter MacCallum Cancer Centre, Melbourne, Australia and of the National Centre for Infections in Cancer, a Centre of Research Excellence funded by the National Health and Medical Research Council. She leads the Immunocompromised Host Infection Service at Royal Melbourne Hospital.

Her research focusses on diagnosing, preventing and treating opportunistic infections including invasive fungal infections in haematology and transplant patients. She is currently the President of the International Immunocompromised Host Society.

Back to Top | Article Outline

Roy F. Chemaly

Dr Roy F. Chemaly is a Professor of Medicine in the Department of Infectious Diseases, Infection Control & Employee Health at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Dr Chemaly completed his training in infectious diseases and medical microbiology at the Cleveland Clinic Foundation in Ohio, USA. He is board-certified in internal medicine/infectious diseases, medical quality, and medical microbiology.

During his fellowship, Dr Chemaly completed a master's degree in public health from Northeastern Ohio Universities in Rootstown, Ohio, USA. In addition to his clinical research work in virology and multi-drug resistant organisms, he is the director of the Infection Control program at MD Anderson Cancer Center and the chair of the Infection Control Committee and the chair of the Conflict of Interest Committee. In addition, he was appointed as the chair of the Transplant Infectious Diseases Special Interest Group of the American Society of Bone Marrow Transplantation which is growing under his leadership.

Dr Chemaly devoted his career studying viral infections in immunocompromised patients, specifically those undergoing hematopoietic cell transplantation (HCT) for hematologic malignancies. He published extensively on mechanisms to treat and prevent viral infections in this population. During his tenure at MD Anderson Cancer Center, he established the clinical virology research program and assembled a research team that conducts phase II and phase III clinical trials for new antiviral drugs, desperately needed for our immunocompromised patients, in addition to PI-initiated trials and lab protocols. He led and successfully completed more than 15 international and national clinical trials and several studies focusing on diagnosis and management of viral infections; data from which have been presented nationally and internationally with subsequent publications of more than 140 manuscripts in high-impact journals. Dr Chemaly's work has been reported in numerous peer-reviewed journals including New England Journal of Medicine, Blood, Journal of Infectious Diseases, and Clinical Infectious Diseases.

Back to Top | Article Outline

Tristan W. Clark

Dr Tristan W. Clark is an Infectious Diseases Physician at University Hospitals Southampton NHS trust and an Associate Professor at the University of Southampton, UK. His research is focused on clinical trials of vaccines, antivirals and diagnostic devices for influenza and other respiratory viruses.

He has published articles in the New England Journal of Medicine and Lancet series journals. He holds an NIHR post-doctoral fellowship to evaluate the clinical impact and cost effectiveness of molecular point-of-care tests for influenza and other respiratory viruses.

Back to Top | Article Outline

Matteo Bassetti

Dr Matteo Bassetti is the Head of the Infectious Diseases Division of the Santa Maria Misericordia University Hospital in Udine and Associate Professor of Infectious Diseases at the University of Udine, Italy. Dr Bassetti studied at the University of Genoa School of Medicine, Italy, and continued his medical education at the Yale University School of Medicine, New Haven, USA with an Infectious Diseases fellowship.

Dr Bassetti is chair of the Critically Ill Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the secretary of the Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC). Dr Bassetti is also the co-chair of the Intra-abdominal Infections Study Group and secretary of the Bone, Skin and Soft Tissue Infections of the International Society of Chemotherapy (ISC). He is the vice-president of Italian Society of Anti-infective Therapy (SITA). He is member-elected (2018–2022) of International Council of the Immunocompromised Host Society (ICHS).

He also serves on the editorial board of several journals including Intensive Care Medicine (Associate-Section Editor), Nature Scientific Reports, Italian Journal of Medicine (Section Editor), Drugs in Context (Associate editor), Journal of Infection and Public Health, Journal of Global Antimicrobial Resistance, Reviews in Medical Microbiology, GMS Infectious Diseases, Journal of Chemotherapy, Infectious Disease, Clinical Microbiology and Antimicrobial Chemotherapy and is a reviewer for several international journals. He is an author or co-author of more than 350 papers (H index 51; 10500 citations) published in International peer-review journals on antibiotic therapy, fungal infections, antimicrobial resistances, infections in immunocompromised patients and critically ill patients.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.